Form 4: Tourmaline Bio Director Sells Shares in Novartis Merger

Tourmaline Bio director Sapna Srivastava disposed of all common stock and stock options following the completion of the acquisition by Novartis AG for $48.00 per share.

Summary

• Sapna Srivastava, a Director of Tourmaline Bio, Inc. (TRML), reported the disposition of all her beneficial ownership in the company.
• These transactions occurred on October 28, 2025, coinciding with the completion of the acquisition of Tourmaline Bio by Novartis AG.
• Under the terms of the Merger Agreement dated September 8, 2025, Novartis AG's subsidiary, Torino Merger Sub Inc., acquired all outstanding common stock of Tourmaline Bio for $48.00 per share in cash.
• Srivastava disposed of 518 shares of common stock, receiving $48.00 per share.
• She also disposed of 46,800 employee stock options (20,000 at $9.46 exercise price, 10,000 at $13.91, and 16,800 at $18.73), which were converted into cash payments based on the difference between the $48.00 merger consideration and their respective exercise prices.
• Following these transactions, Srivastava holds no beneficial ownership in Tourmaline Bio, Inc.

Sentiment

Score: 8

Explanation: The filing confirms the successful completion of the acquisition of Tourmaline Bio by Novartis AG, resulting in a cash payout for shareholders and option holders, which is generally a positive outcome for investors.

Positives

• Shareholders of Tourmaline Bio, Inc. received a cash payment of $48.00 per share, representing a definitive value for their investment.
• Holders of in-the-money employee stock options received cash payouts, monetizing their equity incentives.

Negatives

• Tourmaline Bio, Inc. ceased to be an independent publicly traded company, removing its stock from public markets.
• The reporting person, Sapna Srivastava, no longer holds any equity interest in the company.

Future Outlook

The filing reports a completed acquisition, so there is no forward-looking guidance for Tourmaline Bio as an independent entity.

Industry Context

This acquisition reflects ongoing consolidation within the biotechnology and pharmaceutical sectors, where larger companies like Novartis acquire smaller firms to expand their pipelines or market presence.

Stakeholder Impact

• Shareholders: Received $48.00 cash per share for their common stock.
• Option Holders: Received cash payouts for their in-the-money employee stock options.

Key Dates

Keywords

Tourmaline Bio, TRML, Novartis, Merger, Acquisition, Tender Offer, Form 4, Insider Transaction, Stock Options, Common Stock, Beneficial Ownership